Northern Trust
SGP

Northern Trust’s SpyGlass Pharma SGP Stock Holding History

Northern Trust’s Portfolio SGP Stock Details SGP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.84M Buy
82,451
+61,589
+295% +$1.34M ﹤0.01% 3180
2026
Q1 		$541K Buy
+20,862
New +$561K ﹤0.01% 3588

Other funds holding SGP

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust's SGP Position: Q2 2026 in Review

Northern Trust increased its SpyGlass Pharma (SGP) stake by 295% in Q2 2026, buying an estimated $1.34M and bringing the position to 82,451 shares worth $1.84M. The position accounts for ﹤0.01% of the portfolio, ranked #3180.

Northern Trust first reported a position in SGP in Q1 2026 and has held it in 2 quarters since. 52 funds tracked by Wall St. Rank hold SGP as of Q2 2026.

  • Northern Trust held 82,451 shares of SpyGlass Pharma worth $1.84M as of Q2 2026.
  • Northern Trust bought 61,589 SpyGlass Pharma shares in Q2 2026, an estimated $1.34M.
  • SpyGlass Pharma made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #3180 holding.
  • Northern Trust first reported a position in SpyGlass Pharma in Q1 2026 and has held it in 2 quarters since.
  • 52 funds tracked by Wall St. Rank held SpyGlass Pharma as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.